Drug Trial Radar · NCT05222906
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Apr 18, 2022
Primary completion
Oct 2, 2025
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and \<18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.
Conditions
- Gaucher's Disease Type III
Interventions
VenglustatDrug
tablet; oral
imigluceraseDrug
sterile lyophilized product; intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Scale for Assessment and Rating of Ataxia (SARA) modified total scoreTime frame: From baseline to Week 52
- Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index scoreTime frame: From baseline to Week 52
Locations
22 sites in 11 countries. Site status is shown where the registry gives one.
Yale University School of Medicine - Investigational Site Number: 8400003
New Haven, Connecticut
University of Iowa - Investigational Site Number: 8400002
Iowa City, Iowa
Texas Oncology - Medical City Dallas Site Number : 8400008
Dallas, Texas
Lysosomal & Rare Disorders Research & Treatment Center, Inc - Investigational Site Number: 8400001
Fairfax, Virginia
Hospital de Ninos - Investigational Site Number: 320001
Buenos Aires, Argentina
Children's Hospital Research Institute of Manitoba - Investigational Site Number: 1240001
Winnipeg, Manitoba, Canada
Peking Union Medical College Hospital - Investigational Site Number: 1560001
Beijing, China
The First Affiliated Hospital - Investigational Site Number: 1560002
Guangzhou, China
Xinhua Hospital - Investigational Site Number: 1560004
Shanghai, China
National Taiwan University Hospital-Investigational Site Number: 1580001
Taipei, Taiwan, China
47-87, boulevard de l'hôpital - Investigational Site Number: 2500003
Paris, France
Hopital Necker - Investigational Site Number: 2500001
Paris, France
SphinCS GmbH - Investigational Site Number: 2760001
Hochheim am Main, Germany
Debreceni Egyetem, Klinikai Központ, Reumatológiai Klinika - Investigational Site Number: 3480001
Debrecen, Hungary
Azienda Ospedaliera Universitaria (AOU) "Federico II" - Investigational Site Number: 3800002
Naples, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Investigational Site Number : 3800003
Milan, Lombardy, Italy
Tohoku University School of Medicine - Investigational Site Number: 3920001
Sendai, Japan
Odawara Municipal Hospital-Investigational Site Number : 3920002
Odawara, Kanagawa, Japan
Cukurova University Medical School Hospital-Investigational Site Number : 7920001
Adana, Turkey (Türkiye)
Gazi University Medical Hospital-Investigational Site Number : 7920002
Ankara, Turkey (Türkiye)
Istanbul University Medical Faculty Hospital-Investigational Site Number : 7920004
Istanbul, Turkey (Türkiye)
Investigational Site Number : 8260001
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.